Calidi Biotherapeutics (CLDI) Net Shares Issued and Repurchased (2023 - 2025)

Calidi Biotherapeutics has reported Net Shares Issued and Repurchased for 3 years, with the latest figure at $217000.0 in Q4 2025.

• On a quarterly basis, Net Shares Issued and Repurchased fell 5.24% year-over-year to $217000.0 in Q4 2025; TTM through Dec 2025 was $217000.0, a 5.24% decrease from a year earlier, with the FY2025 full-year figure at $217000.0, down 5.24% from the prior year.
• Net Shares Issued and Repurchased was $217000.0 for Q4 2025 at Calidi Biotherapeutics, up from $13000.0 in the prior quarter.
• The five-year high for Net Shares Issued and Repurchased was $619000.0 in Q4 2023, with the low at $13000.0 in Q1 2025.
• Average Net Shares Issued and Repurchased over 3 years is $224600.0, with a median of $217000.0 recorded in 2025.
• The largest YoY upside for Net Shares Issued and Repurchased was 5.24% in 2025 against a maximum downside of 71.11% in 2025.
• Over 3 years, Net Shares Issued and Repurchased stood at $619000.0 in 2023, then sank by 63.0% to $229000.0 in 2024, then slipped by 5.24% to $217000.0 in 2025.
• The last three Net Shares Issued and Repurchased figures came in at $217000.0 (Q4 2025), $13000.0 (Q1 2025), and $229000.0 (Q4 2024), per Business Quant data.